Brind.

The FDA approved Korlym for Cushing's syndrome on July 6, 2025.

1 report, 0 independent Updated Jul 6

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Who's involved

What this event is mainly about

FDA Corcept Therapeutics

How it developed

Newest first. Tap a step to see who reported it.

Jun 8A trial was conducted on July 4, 2025, testing the product Korlym for diabetes.Sub-event
Jul 6FDA approved Korlym for Cushing's syndrome.

Keep exploring

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Corcept Therapeutics
American pharmaceutical company
- Corcept Therapeutics made required filings with the SEC regarding institutional holdings on June 16, 2026.Mon 03:27

Coverage

Newest first; wire copies grouped

Jul 6Unknown outlet